198 related articles for article (PubMed ID: 34839105)
21. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
Chen W; Zhang J; Huang L; Chen L; Zhou Y; Tang D; Xie Y; Wang H; Huang C
Clin Breast Cancer; 2019 Feb; 19(1):e239-e246. PubMed ID: 30472074
[TBL] [Abstract][Full Text] [Related]
22. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.
Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
[TBL] [Abstract][Full Text] [Related]
24. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Pestrin M; Bessi S; Puglisi F; Minisini AM; Masci G; Battelli N; Ravaioli A; Gianni L; Di Marsico R; Tondini C; Gori S; Coombes CR; Stebbing J; Biganzoli L; Buyse M; Di Leo A
Breast Cancer Res Treat; 2012 Jul; 134(1):283-9. PubMed ID: 22476856
[TBL] [Abstract][Full Text] [Related]
25. The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer.
Abdallah EA; Braun AC; Flores BCTCP; Senda L; Urvanegia AC; Calsavara V; Fonseca de Jesus VH; Almeida MFA; Begnami MD; Coimbra FJF; da Costa WL; Nunes DN; Dias-Neto E; Chinen LTD
Oncologist; 2019 Sep; 24(9):e854-e863. PubMed ID: 30846515
[TBL] [Abstract][Full Text] [Related]
26. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers characterization of circulating tumour cells in breast cancer patients.
Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
[TBL] [Abstract][Full Text] [Related]
29. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
[TBL] [Abstract][Full Text] [Related]
31. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
[TBL] [Abstract][Full Text] [Related]
35. Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases.
Sanches SM; Braun AC; Calsavara VF; Barbosa PNVP; Chinen LTD
Clinics (Sao Paulo); 2021; 76():e2971. PubMed ID: 34644733
[TBL] [Abstract][Full Text] [Related]
36. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
[TBL] [Abstract][Full Text] [Related]
38. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.
Frithiof H; Welinder C; Larsson AM; Rydén L; Aaltonen K
J Transl Med; 2015 Apr; 13():126. PubMed ID: 25896421
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer.
Huai J; Cao M; Jiang Y; Yang X; Zhu Y; Si Y; Xu M; Shen C; Han T; Lian X
Biomed Res Int; 2021; 2021():6388492. PubMed ID: 34901275
[TBL] [Abstract][Full Text] [Related]
40. HER2-positive circulating tumor cells in breast cancer.
Ignatiadis M; Rothé F; Chaboteaux C; Durbecq V; Rouas G; Criscitiello C; Metallo J; Kheddoumi N; Singhal SK; Michiels S; Veys I; Rossari J; Larsimont D; Carly B; Pestrin M; Bessi S; Buxant F; Liebens F; Piccart M; Sotiriou C
PLoS One; 2011 Jan; 6(1):e15624. PubMed ID: 21264346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
